Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
10x Genomics, Inc. (TXG) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "10x Genomics Reports Second Quarter 2023 Financial Results"
07/20/2023 8-K Quarterly results
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "10x Genomics Wins Permanent Injunction Against NanoString’s CosMx Products 10x Genomics is seeking additional injunctions to protect its intellectual property"
11/02/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
08/03/2022 8-K Cost Associated with Exit or Disposal Activities  Interactive Data
07/14/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/16/2022 8-K Quarterly results
Docs: "10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022 FY 2021 revenue growth of 64% and Q4 2021 revenue growth of 28% over the corresponding periods of 2020"
11/03/2021 8-K Quarterly results
Docs: "10x Genomics Reports Third Quarter 2021 Financial Results"
08/04/2021 8-K Quarterly results
07/27/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "SETTLEMENT AND PATENT CROSS LICENSE AGREEMENT",
"10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad"
06/15/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "10x Genomics Reports Third Quarter 2020 Financial Results"
10/13/2020 8-K Quarterly results
10/05/2020 8-K Quarterly results
08/11/2020 8-K Quarterly results
06/18/2020 8-K Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 15, 2020 10x Genomics, Inc. Delaware 001-39035 45-5614458 6230 Stoneridge Mall Road Pleasanton, California 94588 401-7300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ..."
05/11/2020 8-K Quarterly results
Docs: "10x Genomics Reports First Quarter 2020 Financial Results"
04/09/2020 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "10x Genomics Provides COVID-19 Business Impact Update and Response"
04/01/2020 8-K Regulation FD Disclosure
03/26/2020 8-K Quarterly results
02/18/2020 8-K Quarterly results
Docs: "10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance"
12/19/2019 8-K Quarterly results
12/12/2019 8-K Regulation FD Disclosure
12/11/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 11, 2019 10x Genomics, Inc. Delaware 001-39035 45-5614458 6230 Stoneridge Mall Road Pleasanton, California 94588 401-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Ex..."
12/10/2019 8-K Regulation FD Disclosure
11/25/2019 8-K Regulation FD Disclosure
11/07/2019 8-K Quarterly results
Docs: "10x Genomics Reports Third Quarter 2019 Financial Results and Provides 2019 Revenue Guidance"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy